Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509867 | 1.00 | BCHE (0.39) | BCHEKLK5SMN1; SMN2LMNATP53 | |
| SCHEMBL6235252 | 0.88 | BCHE (0.42) | BCHESMN1; SMN2LMNACHRM2CHRM4 | |
| SCHEMBL6235253 | 0.88 | BCHE (0.42) | BCHESMN1; SMN2LMNACHRM2CHRM4 | |
| SCHEMBL8346874 | 0.87 | BCHE (0.42) | BCHESMN1; SMN2LMNATP53TSHR | |
| SCHEMBL1509754 | 0.86 | BCHE (0.39) | BCHESMN1; SMN2LMNATP53TSHR | |
| SCHEMBL1509753 | 0.86 | BCHE (0.39) | BCHESMN1; SMN2LMNATP53TSHR | |
| SCHEMBL5496992 | 0.80 | CTRB1 (0.52) | KLK5LMNATP53TSHRMEN1 | |
| SCHEMBL5496996 | 0.80 | CTRB1 (0.52) | KLK5LMNATP53TSHRMEN1 | |
| SCHEMBL5498366 | 0.76 | KCNQ1 (0.41) | KLK5 | |
| SCHEMBL5498362 | 0.76 | KCNQ1 (0.41) | KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2295054-A1 | Ice inhibitors for the treatment of autoinflammatory diseases | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1778221-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-12-01 | — | — | US | disclosed |
| EP-1499898-A2 | REGULATION OF TNF-ALPHA | Vertex Pharmaceuticals Incorporated (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040048797-A1 | Regulation of TNF-alpha | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-11 | — | — | US | disclosed |
| WO-2003088917-A2 | REGULATION OF TNF-ALPHA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048797-A1 | Regulation of TNF-alpha | TNF, TNFRSF1A, TNFRSF9 | BCHE 629/4885KLK5 399/4885SMN1; SMN2 3937/4885 |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | IL1B, IL1A, NFKBIA | BCHE 1917/4885KLK5 1800/4885SMN1; SMN2 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.